Affinage

ARCN1

Coatomer subunit delta · UniProt P48444

Round 2 corrected
Length
511 aa
Mass
57.2 kDa
Annotated
2026-04-28
130 papers in source corpus 14 papers cited in narrative 12 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ARCN1 encodes δ-COP, a core subunit of the heptameric COPI coatomer complex that coats transport vesicles mediating retrograde and anterograde trafficking at the Golgi apparatus. The coatomer is recruited en bloc from the cytosol to Golgi membranes by ARF1-GTP, and GTP hydrolysis by ARF1 drives subsequent vesicle uncoating; ARCN1 co-purifies and co-fractionates with all six other COPI subunits (COPA, COPB1, COPB2, COPG1, COPG2, COPE) in an evolutionarily conserved ~700 kDa assembly (PMID:1898986, PMID:8599108, PMID:26344197, PMID:35271311). ARCN1 is also an mRNA-binding protein identified by UV-crosslinking interactome capture, and it functions as a host factor required for influenza A virus internalization, a process regulated post-transcriptionally by miR-33a targeting of the ARCN1 3′UTR (PMID:22658674, PMID:26498766). Specific lysine residues on ARCN1 are ubiquitylated, suggesting regulation by the ubiquitin–proteasome system (PMID:21906983).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 1991 High

    Identification of δ-COP as a subunit of the ~700 kDa coatomer complex established that a discrete, pre-formed cytosolic assembly serves as the precursor coat for non-clathrin Golgi transport vesicles.

    Evidence Biochemical purification of cytosolic coatomer, gel filtration, SDS-PAGE, comparison with Golgi-derived coated vesicles

    PMID:1898986

    Open questions at the time
    • Mechanism by which δ-COP contributes to coatomer integrity versus cargo selection was not resolved
    • No structural information on δ-COP contacts within the heptamer
  2. 1996 High

    Reconstitution of COPI vesicle budding revealed that ARF1-GTP recruits the intact coatomer (including δ-COP) to Golgi membranes, and ARF1 GAP-stimulated GTP hydrolysis drives coat disassembly, defining the GTPase cycle that controls COPI vesicle formation.

    Evidence Cell-free vesicle budding reconstitution, ARF1 GAP cloning, brefeldin A redistribution assays

    PMID:8533093 PMID:8599108

    Open questions at the time
    • Direct contacts between δ-COP and ARF1 or membrane lipids were not mapped
    • Relative contributions of individual COP subunits to cargo recognition remained unclear
  3. 2000 Medium

    Live-cell imaging demonstrated that COPI coat assembly and disassembly at the Golgi is rapid and continuous, placing δ-COP within a dynamic trafficking cycle rather than a static structural coat.

    Evidence GFP-tagged COPI components, FRAP, time-lapse fluorescence microscopy

    PMID:11031247

    Open questions at the time
    • δ-COP-specific dynamics were not separated from bulk coatomer behavior
    • Whether δ-COP participates in anterograde versus retrograde vesicles differentially was not addressed
  4. 2012 Medium

    Unbiased UV-crosslinking interactome capture revealed δ-COP as an mRNA-binding protein, suggesting a moonlighting function in RNA biology beyond membrane trafficking.

    Evidence UV crosslinking, oligo(dT) capture, quantitative mass spectrometry in HeLa cells

    PMID:22658674

    Open questions at the time
    • RNA targets and binding specificity of δ-COP were not identified
    • Functional significance of RNA binding was not tested
  5. 2015 Medium

    miR-33a was shown to suppress ARCN1 expression via its 3′UTR, and ARCN1 knockdown phenocopied miR-33a overexpression by blocking influenza A virus internalization; rescue with ectopic ARCN1 confirmed it is a required host factor for virus entry.

    Evidence Luciferase 3′UTR reporter, siRNA knockdown, ectopic overexpression rescue, viral replication assays

    PMID:26498766

    Open questions at the time
    • Whether ARCN1's role in virus internalization depends on COPI vesicle trafficking or an independent mechanism was not determined
    • Generalizability to other enveloped viruses not tested
  6. 2015 High

    Cross-species biochemical co-fractionation established that the heptameric COPI coatomer including δ-COP is an ancient, conserved assembly across metazoa, underscoring its essential housekeeping role.

    Evidence Biochemical co-fractionation across multiple metazoan species coupled with quantitative mass spectrometry

    PMID:26344197

    Open questions at the time
    • Species-specific functional specializations of δ-COP were not explored
  7. 2021 High

    Replicated AP-MS across two cell lines and BioID proximity labeling confirmed ARCN1 interactions with all COPI subunits and localized the protein to the Golgi/COPI vesicle interface, while cell-line-specific differences hinted at context-dependent complex remodeling.

    Evidence AP-MS in HEK293T and HCT116 (BioPlex 3.0); BioID proximity biotinylation in HEK293 cells

    PMID:33961781 PMID:34079125

    Open questions at the time
    • Nature and functional consequence of cell-type-specific interaction differences unknown
    • Whether δ-COP engages with sub-stoichiometric regulatory partners at the Golgi was not resolved
  8. 2022 High

    Endogenous GFP tagging and confocal imaging definitively confirmed Golgi localization and co-localization with the coatomer, while AP-MS from the endogenous locus recovered the intact COPI complex as the primary interaction network.

    Evidence CRISPR endogenous GFP tagging, confocal live-cell imaging, AP-MS of endogenously tagged ARCN1 in HEK293T

    PMID:35271311

    Open questions at the time
    • No high-resolution structural data for δ-COP within the assembled coatomer on membranes
    • Specific cargo-binding surfaces on δ-COP remain unmapped

Open questions

Synthesis pass · forward-looking unresolved questions
  • The direct structural contacts of δ-COP within the coatomer heptamer, its specific contributions to cargo selection versus membrane deformation, and the functional significance of its mRNA-binding activity remain unresolved.
  • No atomic-resolution structure of δ-COP within the human COPI coat
  • Cargo molecules directly recognized by δ-COP have not been identified
  • Functional role of ARCN1 RNA binding is unexplored

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005198 structural molecule activity 3 GO:0003723 RNA binding 1
Localization
GO:0005794 Golgi apparatus 3 GO:0005829 cytosol 2 GO:0031410 cytoplasmic vesicle 2
Pathway
R-HSA-5653656 Vesicle-mediated transport 5 R-HSA-9609507 Protein localization 2
Complex memberships
COPI coatomer

Evidence

Reading pass · 12 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1991 ARCN1 (δ-COP) was identified as a subunit of the 'coatomer' complex, a cytosolic protein complex of ~700 kDa containing seven polypeptides (α-, β-, γ-, δ-COP and three smaller subunits) that constitutes the coat of non-clathrin-coated Golgi transport vesicles. The coatomer was purified from cytosol and shown to contain the same coat proteins found on Golgi-derived coated vesicles, establishing it as the precursor complex for COPI vesicle coat assembly. Biochemical purification of cytosolic complex, gel filtration, SDS-PAGE characterization, and comparison with isolated Golgi-coated vesicles Nature High 1898986
1996 ARCN1 (δ-COP) functions as part of the COPI coat complex that mediates vesicle budding from Golgi membranes, with coat proteins serving dual roles: shaping the transport vesicle and selecting cargo molecules by direct or indirect interaction. ARF1 (an ADP-ribosylation factor GTPase) recruits the coatomer to Golgi membranes in a GTP-dependent manner, and GTP hydrolysis by ARF1 (facilitated by ARF1 GAP) drives uncoating. Cell-free reconstitution of vesicle budding, genetic and biochemical epistasis, ARF1 GAP cloning and Golgi localization studies (brefeldin A redistribution assay) Science High 8533093 8599108
2000 Live-cell imaging using GFP-tagged secretory pathway components demonstrated that COPI-coated vesicles (containing δ-COP/ARCN1) are highly dynamic structures involved in continuous Golgi membrane trafficking, and that COPI coat assembly/disassembly cycles rapidly at Golgi membranes as part of the anterograde and retrograde transport machinery. Live-cell fluorescence microscopy, FRAP (fluorescence recovery after photobleaching), GFP chimera time-lapse imaging of secretory organelle dynamics Annual review of cell and developmental biology Medium 11031247
2012 ARCN1 was identified as an mRNA-binding protein in the HeLa cell mRNA interactome by UV crosslinking-based 'interactome capture,' suggesting an unexpected role for this COPI coatomer subunit in RNA biology beyond its canonical membrane trafficking function. UV crosslinking of RNA-protein complexes, oligo(dT) capture, quantitative mass spectrometry (interactome capture) Cell Medium 22658674
2012 ARCN1 was detected as a component of the human coatomer/COPI complex by size-exclusion chromatography coupled with quantitative mass spectrometry, co-eluting with other COP subunits (α-, β-, γ-, ε-COP) in a high-molecular-weight fraction consistent with the intact heptameric coatomer complex in human cells. Size-exclusion chromatography of native cell extracts combined with quantitative mass spectrometry (SILAC) Nature methods Medium 22863883
2015 MicroRNA-33a (miR-33a) was shown to target the 3′UTR of ARCN1, suppressing ARCN1 protein expression. Knockdown of ARCN1 phenocopied miR-33a overexpression in inhibiting influenza A virus replication at the virus internalization stage, and ectopic re-expression of ARCN1 partially rescued the inhibitory effect of miR-33a on viral replication, establishing ARCN1 as a host factor required for efficient influenza A virus internalization. Luciferase 3′UTR reporter assay, immunoblotting, siRNA knockdown of ARCN1, ectopic ARCN1 overexpression rescue experiment, viral replication assays The Journal of general virology Medium 26498766
2015 ARCN1 was identified within the coatomer protein complex in a large-scale conservation map of metazoan protein complexes, confirming that the heptameric COPI coatomer (including ARCN1/δ-COP) is an ancient, evolutionarily conserved assembly present across diverse metazoan species and functioning in core cellular housekeeping (Golgi trafficking). Biochemical co-fractionation across multiple metazoan species coupled with quantitative mass spectrometry; cross-species conservation analysis Nature High 26344197
2017 ARCN1 interactions were detected by affinity-purification mass spectrometry in the BioPlex 2.0 human interactome, placing ARCN1 within a protein community corresponding to the COPI coatomer complex (interacting with COPA, COPB1, COPB2, COPG1, COPG2, COPE) and providing a systems-level interaction landscape for this trafficking complex. Affinity-purification mass spectrometry (AP-MS) using FLAG-tagged bait proteins in HEK293T cells; CompPASS scoring for interaction confidence Nature Medium 28514442
2021 BioPlex 3.0 AP-MS in both HEK293T and HCT116 cells confirmed ARCN1 interactions with all other COPI coatomer subunits (COPA, COPB1, COPB2, COPG1/2, COPE) in both cell lines, with cell-line-specific differences in interaction partners revealing potential context-dependent remodeling of the coatomer complex. Affinity-purification mass spectrometry (AP-MS) in two human cell lines (293T and HCT116); comparative interactome analysis Cell High 33961781
2021 Proximity-dependent biotinylation (BioID) in HEK293 cells placed ARCN1 at the Golgi apparatus/COPI vesicle interface, with its proximity interactome enriched for other COPI subunits and Golgi-resident proteins, confirming its subcellular localization at the Golgi membrane in living cells. BioID proximity biotinylation coupled with mass spectrometry; subcellular localization prediction from proximity interaction profiles Nature Medium 34079125
2022 Endogenous GFP tagging and confocal live-cell imaging in the OpenCell project confirmed ARCN1 localization to the Golgi apparatus and demonstrated co-localization with other coatomer subunits. AP-MS of endogenously tagged ARCN1 recovered the intact coatomer complex (COPA, COPB1, COPB2, COPG1, COPG2, COPE) as its primary interactors. CRISPR-based endogenous GFP tagging, confocal live-cell imaging, AP-MS of endogenously tagged protein in HEK293T cells Science High 35271311
2011 ARCN1 was identified as a ubiquitylation substrate in global proteomics screens, with specific lysine residues on ARCN1 detected as diglycine-modified (ubiquitylated) sites, indicating that ARCN1 protein stability or function is regulated by the ubiquitin-proteasome system. Immunoaffinity enrichment of diglycine-modified peptides with anti-diGly antibody followed by high-resolution mass spectrometry (quantitative ubiquitinome profiling) Molecular cell / Molecular & cellular proteomics Low 21890473 21906983

Source papers

Stage 0 corpus · 130 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 1718 22658674
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2011 Systematic and quantitative assessment of the ubiquitin-modified proteome. Molecular cell 1334 21906983
2009 Defining the human deubiquitinating enzyme interaction landscape. Cell 1282 19615732
2009 Systemic manifestations and comorbidities of COPD. The European respiratory journal 1179 19407051
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
2015 A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 1015 26496610
2020 A reference map of the human binary protein interactome. Nature 849 32296183
2018 VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell discovery 829 29507755
1996 Coat proteins and vesicle budding. Science (New York, N.Y.) 789 8599108
2006 Mortality in COPD: Role of comorbidities. The European respiratory journal 763 17138679
2011 A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Molecular & cellular proteomics : MCP 749 21890473
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2012 A census of human soluble protein complexes. Cell 689 22939629
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2017 Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science (New York, N.Y.) 533 28302793
1991 'Coatomer': a cytosolic protein complex containing subunits of non-clathrin-coated Golgi transport vesicles. Nature 444 1898986
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2015 A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface. Cell 433 26638075
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
2010 Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science (New York, N.Y.) 421 20360068
2005 Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome research 409 16344560
2015 Panorama of ancient metazoan macromolecular complexes. Nature 407 26344197
2000 Secretory protein trafficking and organelle dynamics in living cells. Annual review of cell and developmental biology 380 11031247
2011 Global identification of modular cullin-RING ligase substrates. Cell 354 21963094
2020 Oxidative stress-based therapeutics in COPD. Redox biology 346 32336666
2021 A proximity-dependent biotinylation map of a human cell. Nature 339 34079125
2014 A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. Cell 325 25036637
2015 The relationship between COPD and lung cancer. Lung cancer (Amsterdam, Netherlands) 323 26363803
2016 Lung microbiome dynamics in COPD exacerbations. The European respiratory journal 305 26917613
1995 The ARF1 GTPase-activating protein: zinc finger motif and Golgi complex localization. Science (New York, N.Y.) 294 8533093
2020 The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature 292 32322062
2000 Oxidants/antioxidants and COPD. Chest 284 10843965
2012 A high-throughput approach for measuring temporal changes in the interactome. Nature methods 273 22863883
2019 Benralizumab for the Prevention of COPD Exacerbations. The New England journal of medicine 265 31112385
2016 The cell proliferation antigen Ki-67 organises heterochromatin. eLife 265 26949251
2010 Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site level. Molecular & cellular proteomics : MCP 262 21139048
2009 Role of HDAC2 in the pathophysiology of COPD. Annual review of physiology 242 18817512
2004 Alveolar macrophages as orchestrators of COPD. COPD 242 16997739
2008 Obesity and the lung: 5. Obesity and COPD. Thorax 228 19020276
2020 COVID-19 and COPD. The European respiratory journal 215 32817205
2008 Pulmonary vascular involvement in COPD. Chest 199 18842913
2019 Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. Journal of thoracic disease 198 31737341
2002 Systemic effects in COPD. Chest 195 12010840
2016 Senescence in COPD and Its Comorbidities. Annual review of physiology 190 27959617
2018 PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis. Autophagy 187 30290714
2005 COPD: current therapeutic interventions and future approaches. The European respiratory journal 176 15929966
2013 Pathophysiology of muscle dysfunction in COPD. Journal of applied physiology (Bethesda, Md. : 1985) 153 23519228
2015 COPD: balancing oxidants and antioxidants. International journal of chronic obstructive pulmonary disease 145 25673984
2019 Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. Journal of thoracic disease 132 31737343
2016 COPD and the microbiome. Respirology (Carlton, Vic.) 123 26852737
2014 Cytokine inhibition in the treatment of COPD. International journal of chronic obstructive pulmonary disease 122 24812504
2014 Clinical issues of mucus accumulation in COPD. International journal of chronic obstructive pulmonary disease 115 24493923
2006 Reduced histone deacetylase in COPD: clinical implications. Chest 111 16424426
2019 Women and COPD: do we need more evidence? European respiratory review : an official journal of the European Respiratory Society 109 30814138
2022 Pathological Mechanism and Targeted Drugs of COPD. International journal of chronic obstructive pulmonary disease 108 35855746
2004 Genetics of COPD. Chest 99 15136409
2010 Inhaled corticosteroids in COPD: a controversy. Respiration; international review of thoracic diseases 96 20501985
2012 Antioxidant pharmacological therapies for COPD. Current opinion in pharmacology 95 22349417
2019 Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update. Journal of thoracic disease 94 31737350
2018 PINK1-PARK2-mediated mitophagy in COPD and IPF pathogeneses. Inflammation and regeneration 93 30386443
2021 Natural history and mechanisms of COPD. Respirology (Carlton, Vic.) 89 33506971
2006 Emerging role of MAP kinase pathways as therapeutic targets in COPD. International journal of chronic obstructive pulmonary disease 89 18046891
2019 Chemokines in COPD: From Implication to Therapeutic Use. International journal of molecular sciences 84 31174392
2008 Emerging pharmacotherapies for COPD. Chest 84 19059958
2002 Cytokines and therapy in COPD: a promising combination? Chest 74 12010854
2002 Neutrophil elastase inhibitors as treatment for COPD. Expert opinion on investigational drugs 73 12084007
2014 Management and prevention of exacerbations of COPD. BMJ (Clinical research ed.) 70 25245156
2002 Airways inflammation and COPD: epithelial-neutrophil interactions. Chest 69 12010843
2006 Antioxidant therapeutic targets in COPD. Current drug targets 68 16787173
2018 Mitochondrial Quality Control in COPD and IPF. Cells 67 30042371
2017 Characteristics and potential role of M2 macrophages in COPD. International journal of chronic obstructive pulmonary disease 67 29089751
2009 Associations between statins and COPD: a systematic review. BMC pulmonary medicine 67 19594891
2002 Few smokers develop COPD. Why? Respiratory medicine 67 12195843
2018 Chronic obstructive pulmonary disease (COPD) and lung cancer screening. Translational lung cancer research 66 30050772
2006 Apoptotic mechanisms in the pathogenesis of COPD. International journal of chronic obstructive pulmonary disease 65 18046893
2005 Murine models of COPD. Pulmonary pharmacology & therapeutics 60 16084119
2017 Epithelial and endothelial cell plasticity in chronic obstructive pulmonary disease (COPD). Respiratory investigation 59 28274525
2023 How inhaled corticosteroids target inflammation in COPD. European respiratory review : an official journal of the European Respiratory Society 58 37852657
2016 The inflammasome pathway in stable COPD and acute exacerbations. ERJ open research 58 27730204
2020 Extracellular matrix remodelling in COPD. European respiratory review : an official journal of the European Respiratory Society 56 33208482
2014 Structural alterations of skeletal muscle in copd. Frontiers in physiology 56 24678302
2021 Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD. Antioxidants (Basel, Switzerland) 55 34572965
2006 Antioxidant therapies in COPD. International journal of chronic obstructive pulmonary disease 55 18046899
2021 Protein Biomarkers for COPD Outcomes. Chest 53 33434499
2010 Lasers, stem cells, and COPD. Journal of translational medicine 53 20158898
2000 Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 53 11057087
2010 Pathogenesis of inflammation and repair in advanced COPD. Seminars in respiratory and critical care medicine 52 20496295
2018 Autophagy, selective autophagy, and necroptosis in COPD. International journal of chronic obstructive pulmonary disease 51 30349225
2017 Decreased Serum Sirtuin-1 in COPD. Chest 51 28506610
2009 Endocrinological derangements in COPD. The European respiratory journal 51 19797671
2008 Pulmonary hypertension associated with COPD. International journal of chronic obstructive pulmonary disease 48 18488429
2021 Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome. Archivos de bronconeumologia 47 34172340
2020 Senotherapy: A New Horizon for COPD Therapy. Chest 47 32057805
2014 Network medicine analysis of COPD multimorbidities. Respiratory research 47 25248857
2015 Association between HMGB1 and COPD: A Systematic Review. Mediators of inflammation 45 26798204
2014 Targeting mucus hypersecretion: new therapeutic opportunities for COPD? Drugs 45 24890395
2005 Selectin antagonists : therapeutic potential in asthma and COPD. Treatments in respiratory medicine 45 15813660
2019 Extracellular vesicles in chronic obstructive pulmonary disease (COPD). Journal of thoracic disease 44 31737342
2012 Epigenetics in asthma and COPD. Biochimie 44 22874820
2006 Akt in the pathogenesis of COPD. International journal of chronic obstructive pulmonary disease 44 18046900
2022 New drugs under development for COPD. Minerva medica 43 35142480
2021 Towards Personalized Management of Sarcopenia in COPD. International journal of chronic obstructive pulmonary disease 43 33442246
2020 Sputum microbiome profiling in COPD: beyond singular pathogen detection. Thorax 42 31996401
2014 Epigenetic mechanisms in COPD: implications for pathogenesis and drug discovery. Expert opinion on drug discovery 42 24850530
2019 Targeting HDAC Complexes in Asthma and COPD. Epigenomes 41 34968229
2020 Lung epithelium damage in COPD - An unstoppable pathological event? Cellular signalling 40 31953012
2016 Betulin inhibited cigarette smoke-induced COPD in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 39 27899253
2017 Macrophage phagocytosis cracking the defect code in COPD. Biomedical journal 38 29433833
2015 Molecular pathogenesis of cigarette smoking-induced stable COPD. Annals of the New York Academy of Sciences 38 25639503
2011 Respiratory muscle dysfunction in COPD: from muscles to cell. Current drug targets 38 21194407
2017 Emerging pharmaceutical therapies for COPD. International journal of chronic obstructive pulmonary disease 37 28790817
2010 Atrophy and hypertrophy signalling of the quadriceps and diaphragm in COPD. Thorax 37 20965933
2020 Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update Review. COPD 36 32558592
2008 Translating the COPD transcriptome: insights into pathogenesis and tools for clinical management. Proceedings of the American Thoracic Society 36 19017738
2019 Targeting IL-5 in COPD. International journal of chronic obstructive pulmonary disease 35 31190789
2011 Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Current drug targets 35 21194405
2011 Mast cells and COPD. Pulmonary pharmacology & therapeutics 34 21463700
2022 COPD lung studies of Nrf2 expression and the effects of Nrf2 activators. Inflammopharmacology 33 35441963
2019 Metabolomic signatures of asthma-COPD overlap (ACO) are different from asthma and COPD. Metabolomics : Official journal of the Metabolomic Society 33 31165288
2011 Genetics of COPD. Allergology international : official journal of the Japanese Society of Allergology 33 21778810
2015 MicroRNA-33a disturbs influenza A virus replication by targeting ARCN1 and inhibiting viral ribonucleoprotein activity. The Journal of general virology 32 26498766
2022 Metabolomics of asthma, COPD, and asthma-COPD overlap: an overview. Critical reviews in clinical laboratory sciences 31 36420874
2019 Sphingolipids in COPD. European respiratory review : an official journal of the European Respiratory Society 31 31694841
2013 Development of new drugs for COPD. Current medicinal chemistry 31 22963554
2015 Candidate genes for COPD: current evidence and research. International journal of chronic obstructive pulmonary disease 29 26527870
2014 Sputum ADAM8 expression is increased in severe asthma and COPD. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 29 24147597
2007 A review of etiologies of depression in COPD. International journal of chronic obstructive pulmonary disease 29 18268923
2013 Metabolic derangements in COPD muscle dysfunction. Journal of applied physiology (Bethesda, Md. : 1985) 28 23288549
2015 Prostanoids in Asthma and COPD: Actions, Dysregulation, and Therapeutic Opportunities. Chest 27 26204554